FDA approval: Palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer

Clinical Cancer Research

Volumn 21, Issue 21, 2015, Pages 4760-4766

  Beaver, Julia A ^a   Amiri Kordestani, Laleh ^a   Charlab, Rosane ^a   Chen, Wei ^a   Palmby, Todd ^a   Tilley, Amy ^a   Zirkelbach, Jeanne Fourie ^a   Yu, Jingyu ^a   Liu, Qi ^a   Zhao, Liang ^a   Crich, Joyce ^a   Chen, Xiao Hong ^a   Hughes, Minerva ^a   Bloomquist, Erik ^a   Tang, Shenghui ^a   Sridhara, Rajeshwari ^a   Kluetz, Paul G ^a   Kim, Geoffrey ^a   Ibrahim, Amna ^a   Pazdur, Richard ^a   Cortazar, Patricia ^a   more..

^a Supervision and Adult Learning at Cleveland   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; PALBOCICLIB; PLACEBO; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE DISEASE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENICITY; CCND1 GENE; CDKN2A GENE; COHORT ANALYSIS; CONTINUOUS INFUSION; DEMOGRAPHY; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; ENTEROPATHY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE; GENE AMPLIFICATION; HORMONAL THERAPY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE INJURY; LEUKOPENIA; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL (TOPIC); METABOLISM; METASTASIS; METHODOLOGY; MORTALITY; PATHOLOGY; PATIENT SELECTION; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; PATIENT SELECTION; PIPERAZINES; POSTMENOPAUSE; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RESEARCH DESIGN; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84947204419     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1185     Document Type: Article

References (11)

1. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
2. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifenor Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57.
3. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
4. Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res 2014;16:207.
5. Arnold A, Papanikolaou A. Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 2005;23:4215-24
6. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
7. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009;11:R77.
8. Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015;16:25-35.
9. Code of Federal Regulations: Applications for FDA approval to market a new drug. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. 21 C.F.R. Sect. 2014:314.510.
10. Transcript for the February 8, 2011, meeting of the Oncologic Drugs Advisory Committee [PDF on the Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2011 [cited 2015 Aug 5]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM245644.pdf.
11. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 2015;373:209-19.